Granisetron transdermal system: A new option to help prevent chemotherapy-induced nausea and vomiting

Clinical Journal of Oncology Nursing

Volumn 13, Issue 6, 2009, Pages 711-714

  Schulmeister, Lisa ^a  

^a Oncology Nursing Consultant   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; GRANISETRON; SEROTONIN ANTAGONIST;

ARTICLE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; NAUSEA; NEOPLASM; VOMITING;

ADMINISTRATION, CUTANEOUS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; GRANISETRON; HUMANS; NAUSEA; NEOPLASMS; SEROTONIN ANTAGONISTS; VOMITING;

EID: 77449157055     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/09.CJON.711-714     Document Type: Article

References (17)

1. Brown, M.B., Martin, G.P., Jones, S.A., & Akomeah, F.K. (2006). Dermal and transdermal drug delivery systems: Current and future prospects. Drug Delivery, 13(3), 175-187.
2. Cho, E., Gwak, H., & Chun, I. (2008). Formulation and evaluation of ondansetron nasal delivery systems. International Journal of Pharmaceutics, 349(1-2), 101-107.
3. Diaz del Consuelo, I., Falson, F., Guy, R.H., & Jacques, Y. (2007). Ex vivo evaluation of bioadhesive films for buccal delivery of fentanyl. Journal of Controlled Release, 122(2), 135-140.
4. Hampton, T. (2005). Breaking barriers in transdermal drug delivery. JAMA, 293(17), 2083.
5. Herrstedt, J. (2008). Antiemetics: An update and the MASCC guidelines applied in clinical practice. Nature Clinical Practice. Oncology, 5(1), 32-43.
6. Kaestli, L.Z., Wasilewski-Rasca, A.F., Bonnabry, P., & Vogt-Ferrier, N. (2008). Use of transdermal drug formulations in the elderly. Drugs and Aging, 25(4), 269-280.
7. Kris, M.G., Hesketh, P.J., Somerfield, M.R., Feyer, P., Clark-Snow, R., Koeller, J.M., et al. (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. Retrieved November 1, 2008, from http://www.asco.org/portal/ site/ASCO/menuitem.c543a013502b2a89de91231032004la0/ ?vgnextoid=cf6f8c393c458010VgnVCM100000ed730ad1RCRD
8. National Comprehensive Cancer Network. (2009). NCCN Clinical Practice Guidelines in Oncology™. Antiemesis [v.1.2009]. Retrieved October 27, 2009, from http://www.nccn.org/professionals/physician-gls/PDF/antiemesis.pdf
9. Parekh, D., Miller, M.A., Borys, D., Patel, P.R., & Levsky, M.E. (2008). Transdermal patch medication delivery systems and pediatric poisonings, 2002-2006. Clinical Pediatrics, 47(7), 659-663.
10. Park, E.J., Dodds, J., & Smith, N.B. (2008). Dose comparison of ultrasonic transdermal insulin delivery to subcutaneous insulin injection. International Journal of Nanomedtctne, 3(5), 335-341.
11. Prausnitz, M.R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261-1268.
12. ProStrakan, Inc. (2008a). Clinical and economic data supporting consideration of Sancuso® granisetron transdermal system for chemotherapy-Induced nausea and vomiting. Bedminster, NJ: Author.
13. ProStrakan, Inc. (2008b). Sancuso® (granisetron transdermal system) [Package insert]. Bedminster, NJ: Author.
14. Schulmeister, L. (2005). Transdermal drug patches. Medicine with muscle. Nursing 2005, 35(1), 48-52.
15. Tipton, J.M., McDaniel, R.W., Barbour, L., Johnston, M.P., Kayne, M., LeRoy, P., et al. (2007). Putting Evidence Into Practice: Evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clinical Journal of Oncology Nursing, 11(1), 69-78.
16. U.S. Food and Drug Administration. (2008). FDA approved drug products. Retrieved November 6, 2008, from http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.DrugDetails
17. Wokovich, A.M., Prodduturi, S., Doub, W.H., Hussain, A.S., & Buhse, L.F. (2006). Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. European Journal of Pharmaceutics and Biopharmaceutics, 64(1), 1-8.